Read by QxMD icon Read


Corey J Langer, Shirish M Gadgeel, Hossein Borghaei, Vassiliki A Papadimitrakopoulou, Amita Patnaik, Steven F Powell, Ryan D Gentzler, Renato G Martins, James P Stevenson, Shadia I Jalal, Amit Panwalkar, James Chih-Hsin Yang, Matthew Gubens, Lecia V Sequist, Mark M Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi
BACKGROUND: Limited evidence exists to show that adding a third agent to platinum-doublet chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer (NSCLC) setting. The anti-PD-1 antibody pembrolizumab has shown efficacy as monotherapy in patients with advanced NSCLC and has a non-overlapping toxicity profile with chemotherapy. We assessed whether the addition of pembrolizumab to platinum-doublet chemotherapy improves efficacy in patients with advanced non-squamous NSCLC...
October 10, 2016: Lancet Oncology
Amr S Abu Lila, Masakazu Fukushima, Cheng-Long Huang, Hiromi Wada, Tatsuhiro Ishida
Pemetrexed (PMX) is a key drug for the treatment of malignant pleural mesothelioma (MPM). However, its therapeutic efficacy is cruelly restricted in many clinical settings by the over-expression of thymidylate synthase (TS) gene. Recently, we emphasized the efficacy of locally administered shRNA designed against TS gene in enhancing the cytotoxic effect of PMX against orthotopically implanted MPM cells in tumor xenograft tumor model. In the present study, we investigated the efficacy of systemic, rather than local, delivery of TS RNAi molecule in sensitizing MPM cells to the cytotoxic effect of PMX...
October 14, 2016: Molecular Pharmaceutics
Limin Zhang, Tao Jiang, Chao Zhao, Wei Li, Xuefei Li, Sha Zhao, Xiaozhen Liu, Yijun Jia, Hui Yang, Shengxiang Ren, Caicun Zhou
BACKGROUND: ROS1 rearrangement is a novel molecular subgroup of non-small-cell lung cancer (NSCLC). This study aimed to investigate the efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement. RESULTS: A total of 2309 patients received ROS1 fusion detection and 51(2.2%) patients had ROS1 rearrangement. There was no significant difference between ROS1 fusion-positive and fusion-negative cohorts in demographic data...
October 12, 2016: Oncotarget
Manish K Thakur, Shirish M Gadgeel
Therapy of non-small cell lung cancer (NSCLC) patients has evolved over the past few years with the incorporation of targeted therapy and immune therapy. These changes have increased the importance of prognostic and predictive biomarkers to enable practicing physicians in making the most appropriate treatment decisions for NSCLC patients. A variety of prognostic factors based on clinical and pathologic features determine the overall outcome of the patient and these factors do influence decisions regarding initiation of therapy...
October 2016: Seminars in Respiratory and Critical Care Medicine
Shao-Lun Lu, Feng-Ming Hsu, Kuan-Yu Chen, Chao-Chi Ho, James Chih-Hsin Yang, Jason Chia-Hsien Cheng
Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative radiotherapy (SABR) for oligoprogressive disease during maintenance pemetrexed. All of them had sustained local control of thoracic oligoprogression after the SABR, while maintenance pemetrexed were kept for additionally long progression-free interval. SABR targeting oligoprogression with continued pemetrexed is an effective and safe approach to extend exposure of maintenance pemetrexed, thus maximizing the benefit from it...
May 2016: Case Reports in Oncology
Yiyu Lu, Weiguang Gu, Jin Deng, Hua Yang, Wen Yang
BACKGROUND: Concurrent chemotherapy and radiation is the standard treatment for unresectable stage III Lung adenocarcinoma. However, no optimal concurrent chemotherapeutic regimen has been described. This study aimed to assess concurrent pemetrexed, nedaplatin and thoracic intensity-modulated radiotherapy followed by consolidation pemetrexed/nedaplatin for unresectable Stage IIIA/B lung adenocarcinoma. METHODS: Patients with unresectable stage III lung adenocarcinoma received thoracic intensity-modulated radiotherapy at 60-64 Gy in 30-32 fractions, concurrently with two cycles of 500 mg/m(2) pemetrexed, with nedaplatin doses escalating from 60 mg/m(2) (level 1) to 70 mg/m(2) (level 2) and 80 mg/m(2) (level 3)...
October 7, 2016: BMC Cancer
Puey Ling Chia, Prudence Russell, Andrew M Scott, Thomas John
Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other serosal membranes originating from mesothelial cells that, despite decades of research, continues to have limited therapeutic options and is associated with a poor prognosis. Areas covered: MMs induce a strong inflammatory response that is also associated with neoangiogenesis and activation of proangiogenic factors. Given this, several anti-angiogenic agents have been trialled in a variety of malignancies including mesothelioma...
October 4, 2016: Expert Review of Anticancer Therapy
Kai-Sheng Liao, Chia-Li Wei, Jyh-Cheng Chen, Hao-Yu Zheng, Wen-Ching Chen, Chia-Hung Wu, Tai-Jing Wang, Yi-Shuan Peng, Po-Yuan Chang, Yun-Wei Lin
Pemetrexed, a multitargeted antifolate agent, has demonstrated clinical activity in non-small cell lung cancer (NSCLC) cells. Increased expression of thymidylate synthase (TS) is thought to be associated with resistance to pemetrexed. Astaxanthin exhibits a wide range of beneficial effects including anti-cancer and anti-inflammatory properties. In this study, we showed that down-regulating of TS expression in two NSCLC cell lines, human lung adenocarcinoma H1650 and squamous cell carcinoma H1703 cells, with astaxanthin were associated with decreased MKK1/2-ERK1/2 activity...
September 28, 2016: Regulatory Toxicology and Pharmacology: RTP
Ming-Sound Tsao, Licun Wu, Ghassan Allo, Thomas John, Ming Li, Tetsuzo Tagawa, Isabelle Opitz, Masaki Anraku, Zhihong Yun, Melania Pintilie, Geoffrey Liu, Bethany Pitcher, Ron Feld, Michael R Johnston, Marc de Perrot
PURPOSE: Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with few therapeutic options. The tumor stromal interface is important in MPM, but this is lost in cell lines, the main model used for preclinical studies. We sought to characterise MPM patient derived xenografts (PDX) to determine their suitability as pre-clinical models and whether tumors that engraft reflect a more aggressive biological phenotype. EXPERIMENTAL DESIGN: Fresh tumors were harvested from extrapleural pneumonectomy (EPP), decortication or biopsy samples of 50 MPM patients, and implanted subcutaneously into immunodeficient mice and serially passaged for up to five generations...
September 28, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Giorgio V Scagliotti, Rabab Gaafar, Anna Nowak, Nicholas J Vogelzang, Ute Von Wangenheim, Nassim Morsli, Derek Velema, Sanjay Popat
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
Pingfu Fu, Afshin Dowlati, Nathan Pennell, Neelesh Sharma, Qizhi Yi, Balazs Halmos
PURPOSE: There has been a long-standing interest in the investigation of interactions in science. The objective of the study is to evaluate interaction between EGFR mutation and treatment from randomized, phase II study of chemotherapy versus chemotherapy plus erlotinib in patients with progressive NSCLC following clinical benefit from erlotinib. MATERIALS AND METHODS: Forty-six patients with advanced stage NSCLC and progression from erlotinib were randomized to receive chemotherapy (pemetrexed or docetaxel) or chemotherapy plus erlotinib between 2008 and 2012...
September 16, 2016: Reviews on Recent Clinical Trials
Tindara Franchina, Alessandro Russo, Giuseppina Rosaria Ricciardi, Giuseppina Liguori, Astrid Herberg, Nicola Normanno, Vincenzo Adamo
During the last decade the therapeutic landscape of Non Small Cell Lung Cancer (NSCLC) has profoundly changed with the identification of actionable genetic alterations that defined molecularly selected subgroups of patients with specific clinic-pathological characteristics and increased sensitivity to specific targeted agents. The presence of ROS1 rearrangements defines a small subgroup of lung adenocarcinomas (∼1-2%) with peculiar clinic-pathological characteristics and increased sensitivity to Crizotinib...
August 12, 2016: Cancer Biology & Therapy
Yoshiro Nakahara, Yusuke Takagi, Yukio Hosomi, Akiko Kagei, Tomohiro Yamamoto, Takeshi Sawada, Makiko Yomota, Yusuke Okuma, Shinichiro Mikura, Tatsuru Okamura
BACKGROUND: Repetitive genotyping is useful to assess the genetic evolution of non-small-cell lung cancer (NSCLC) during treatment, but the need for sampling by biopsy is a major obstacle. Digital polymerase chain reaction (PCR) is a promising procedure for the detection of mutant alleles in plasma of cancer patients. METHODS: This prospective study enrolled patients with NSCLC and known epidermal growth factor receptor (EGFR) mutations and who had experienced disease progression during ongoing EGFR-tyrosine kinase inhibitor (TKI) therapy...
2016: OncoTargets and Therapy
Kana Hashimoto, Yusuke Okuma, Yukio Hosomi, Tsunekazu Hishima
BACKGROUND: Desmoplastic malignant pleural mesothelioma (DMM) is rare histological subtype of diffuse malignant pleural mesothelioma (MPM), accounting for 5-10 % of cases. It has a poor prognosis, with direct invasion of the chest wall or lungs and distant metastases. Its pathological characteristics include dense collagen fibers in a storiform pattern. Its pretreatment pathological diagnosis is difficult, with fibrous pleuritis and reactive mesothelial hyperplasia as potential differential diagnoses...
2016: BMC Cancer
Annabel J Sharkey, Kenneth J O'Byrne, Apostolos Nakas, Sara Tenconi, Dean A Fennell, David A Waller
OBJECTIVES: There is little evidence regarding the use of chemotherapy as part of multimodality treatment of malignant pleural mesothelioma (MPM). We aimed to determine whether, in those patients fit for chemotherapy, a delay in this treatment affected survival. MATERIALS AND METHODS: We analysed postoperative variables of 229 patients undergoing either extrapleural pneumonectomy (EPP) (81 patients) or extended pleurectomy-decortication (EPD) (197 patients) for MPM at a single centre...
October 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Mitsunori Higuchi, Yuki Owada, Takuya Inoue, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Takeo Hasegawa, Hiroyuki Suzuki
BACKGROUND: Nivolumab, an immune checkpoint inhibitor, is recently clinically applied to non-small cell lung cancer (NSCLC) treatment, and this causes T cell activation and T cell infiltration to tumor tissue through the blockade of the interaction between programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1). 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) sometimes shows false positive because of the recruitment of neutrophils, lymphocytes, and macrophages...
September 5, 2016: World Journal of Surgical Oncology
Patrick Dorn, Colin Charles Tièche, Ren-Wang Peng, Laurène Froment, Ralph Alexander Schmid, Thomas Michael Marti
BACKGROUND: Lung cancer causes the most cancer deaths worldwide, thus there is a urgent need to develop new treatment options. Concurrent chemoradiotherapy has become a common strategy for the treatment of non-resectable solid tumors including non-small cell lung cancer. Pemetrexed is a folic acid antagonist that inhibits the synthesis of precursor nucleotides, whereas ionizing radiation induces DNA damage, the repair of which is dependent on sufficiently high nucleotide levels. In the clinical setting, the pemetrexed-ionizing radiation combination therapy is administered concomitantly...
2016: Cancer Cell International
Ramiro Vázquez, Simonetta Andrea Licandro, Lucile Astorgues-Xerri, Emanuele Lettera, Nicolò Panini, Michela Romano, Eugenio Erba, Paolo Ubezio, Ezia Bello, Roberta Libener, Sara Orecchia, Federica Grosso, María Eugenia Riveiro, Esteban Cvitkovic, Mohamed Bekradda, Maurizio D'Incalci, Roberta Frapolli
It has recently been reported that a large proportion of human malignant pleural mesothelioma (MPM) cell lines and patient tissue samples present high expression of the c-MYC oncogene. This gene drives several tumorigenic processes and is overexpressed in many cancers. Although c-MYC is a strategic target to restrain cancer processes, no drugs acting as c-MYC inhibitors are available. The novel thienotriazolodiazepine small-molecule bromodomain inhibitor OTX015/MK-8628 has shown potent antiproliferative activity accompanied by c-MYC downregulation in several tumor types...
September 4, 2016: International Journal of Cancer. Journal International du Cancer
Song Tong, Kai Fan, Ke Jiang, Wei Zhai, Bin Fang, Si-Hua Wang, Jian-Jun Wang
BACKGROUND AND AIMS: Infections related to pemetrexed have been reported in clinical trials. It is not yet clear whether this drug increases infection risk or not. This meta-analysis assessed the overall incidence and risk of severe infections (≥ grade 3) associated with the use of pemetrexed in non-small-cell lung cancer patients. METHODS: The databases of PubMed, Embase, and the Cochrane Library were searched for relevant studies published up to December 2015...
September 22, 2016: Current Medical Research and Opinion
Menelaos Zafrakas, Panayiota Papasozomenou, Christos Emmanouilides
AIM: To evaluate the current role of sorafenib, an oral multikinase inhibitor in the treatment of breast cancer. METHODS: An extensive search of the literature until March 2016 was carried out in Medline and, by using the search terms "sorafenib" and "breast cancer". Papers found were checked for further relevant publications. Overall, 21 relevant studies were found, 18 in advanced breast cancer (16 in stage IV and two in stages III-IV) and three in early breast cancer...
August 10, 2016: World Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"